drugset / Trial / NCT03629873
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC combining with auto-HSCT to treat aggressive lymphoma Subjects
Timeline
- Start
- 2018-02-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 1 g | Intravenous |
| Subject | Cytarabine | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |
| Subject | carmustine | Small molecule | 300 mg/m2 | Intravenous |